Resources

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has established a US subsidiary at The Engine in Cambridge, MA.

Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.

Fleet Bioprocessing Ltd has announced the launch of a new contract development service for Lateral Flow Devices (LFDs), expanding its capabilities in response to strong growth in point-of-care and decentralised diagnostics.

Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, explores Biosolutions, defining what they are and their potential to solve global challenges beyond health.

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.

Precision treatments tackling the hardest-to-treat cancers set to be produced from hundreds of tonnes of reprocessed uranium from nuclear reactors

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to a range of a cell therapies.

Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases. Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.

The UK’s used nuclear materials will be recycled to create an evergreen supply of new precision cancer medicines, offering hope for patients with previously untreatable cancers.

London Life Sciences Week kicked off last night with a buzzing reception at Somerset House and we’re looking forward to a jam-packed week of networking and events. Great to see the incredible hard work from the BIA and L&P teams come to life – shining a global light on the incredible UK ecosystem. At the same time, we’re seeing the UK take a leading role in pro-innovation regulation, from last week’s enactment of the Precision Breeding Act to Lawrence Tallon’s insights on the MHRA’s proportionate, strategic future approach, and now need the government to invest in the sector and ensure the commercial environment enables the UK to build on this world-beating foundation.

The Medical Research Council, Wellcome Trust, and Innovate UK have today announced a major new £15.9 million initiative to enable the development of advanced, specific and highly reproducible human-based in vitro models of disease, to make them widely available to researchers in academia and industry.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

MORF-Bio is delighted to announce the successful closing of its pre-seed funding round to accelerate development of its microbial bioinformatics software.